THIRD HARMONIC BIO INC (THRD)

Company Profile

Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. The company is headquartered in San Francisco, California and currently employs 32 full-time employees. The company went IPO on 2022-09-15. The firm is engaged in the development of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company is focused on developing oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company’s clinical studies demonstrate that KIT inhibition is used for the treatment of a range of mast-cell-mediated inflammatory diseases, and that a titratable, oral, intracellular small molecule inhibitor may provide the optimal therapeutic profile against this target.

Company Info

THIRD HARMONIC BIO INC

1700 Montgomery Street, Suite 210

San Francisco CALIFORNIA

P: 12097272457

Employees: 32

Website: https://thirdharmonicbio.com/